Imunon Historical Cash Flow
| IMNN Stock | USD 0.86 0.03 3.61% |
Analysis of Imunon cash flow over time is an excellent tool to project Imunon Inc future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 833.3 K or Capital Expenditures of 269.3 K as it is a great indicator of Imunon ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Imunon Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Imunon Inc is a good buy for the upcoming year.
Imunon |
About Imunon Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Imunon balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Imunon's non-liquid assets can be easily converted into cash.
Imunon Cash Flow Chart
Add Fundamental
Change To Inventory
The increase or decrease in the amount of inventory a company has over a certain period.Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Investments
Securities or assets acquired for generating income or appreciating in value, not used in daily operations.Most accounts from Imunon's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Imunon Inc current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Imunon's Net Borrowings is very stable compared to the past year. As of the 27th of November 2024, Total Cashflows From Investing Activities is likely to grow to about 7.9 M, though Change To Inventory is likely to grow to (51.3 K).
| 2023 | 2024 (projected) | Change To Account Receivables | 61.3K | 79.5K | Stock Based Compensation | 759.0K | 721.1K |
Imunon cash flow statement Correlations
Click cells to compare fundamentals
Imunon Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Imunon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.Moving together with Imunon Stock
| 0.72 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.86 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.9 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Imunon Stock
| 0.87 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.85 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.54 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.4 | PHVS | Pharvaris BV | PairCorr |
| 0.35 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.
The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.014 | Return On Assets (0.67) | Return On Equity (1.48) |
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.